Macy Zou

531 total citations
7 papers, 178 citations indexed

About

Macy Zou is a scholar working on Infectious Diseases, Epidemiology and Animal Science and Zoology. According to data from OpenAlex, Macy Zou has authored 7 papers receiving a total of 178 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Infectious Diseases, 4 papers in Epidemiology and 3 papers in Animal Science and Zoology. Recurrent topics in Macy Zou's work include SARS-CoV-2 and COVID-19 Research (4 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (4 papers). Macy Zou is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (4 papers), Influenza Virus Research Studies (4 papers) and Respiratory viral infections research (4 papers). Macy Zou collaborates with scholars based in Canada. Macy Zou's co-authors include Mel Krajden, Danuta M. Skowronski, Agatha N. Jassem, Romy Olsha, Suzana Sabaiduc, Hugues Charest, Gaston De Serres, Jonathan B. Gubbay, James A. Dickinson and Nathalie Bastien and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Eurosurveillance.

In The Last Decade

Macy Zou

7 papers receiving 171 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Macy Zou Canada	7	115	111	48	28	24	7	178
Nicholas J. Swanson United States	4	62 0.5×	162 1.5×	15 0.3×	20 0.7×	15 0.6×	4	205
Maireid Bull Hong Kong	5	52 0.5×	122 1.1×	30 0.6×	16 0.6×	47 2.0×	10	174
Anwar Isa Abd Elal United States	5	127 1.1×	37 0.3×	12 0.3×	23 0.8×	18 0.8×	5	143
Ana‐Maria Henao‐Restrepo Switzerland	4	125 1.1×	42 0.4×	85 1.8×	20 0.7×	49 2.0×	4	151
Mai-Chi Trieu Norway	10	152 1.3×	79 0.7×	13 0.3×	6 0.2×	92 3.8×	21	209
Francesco Menegale Italy	3	34 0.3×	121 1.1×	50 1.0×	53 1.9×	8 0.3×	8	160
Sergey V. Shulga Russia	7	112 1.0×	38 0.3×	54 1.1×	7 0.3×	40 1.7×	10	120
Mark Anderson United States	8	152 1.3×	96 0.9×	14 0.3×	21 0.8×	21 0.9×	29	239
Ioannis Sitaras United States	9	61 0.5×	84 0.8×	15 0.3×	8 0.3×	15 0.6×	12	129
Jodi Feser United States	7	141 1.2×	56 0.5×	38 0.8×	5 0.2×	26 1.1×	9	158

Countries citing papers authored by Macy Zou

Since Specialization

Citations

This map shows the geographic impact of Macy Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Macy Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Macy Zou more than expected).

Fields of papers citing papers by Macy Zou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Macy Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Macy Zou. The network helps show where Macy Zou may publish in the future.

Co-authorship network of co-authors of Macy Zou

This figure shows the co-authorship network connecting the top 25 collaborators of Macy Zou. A scholar is included among the top collaborators of Macy Zou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Macy Zou. Macy Zou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Skowronski, Danuta M., Solmaz Setayeshgar, Macy Zou, et al.. (2022). Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. The Journal of Infectious Diseases. 226(3). 485–496. 7 indexed citations

Zou, Macy, et al.. (2022). SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada. Open Forum Infectious Diseases. 9(5). ofac178–ofac178. 12 indexed citations

Skowronski, Danuta M., Solmaz Setayeshgar, Macy Zou, et al.. (2021). Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada. Clinical Infectious Diseases. 74(7). 1158–1165. 35 indexed citations

Skowronski, Danuta M., Macy Zou, Catharine Chambers, et al.. (2020). Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010–2011 to 2016–2017. Clinical Infectious Diseases. 71(16). 2285–2288. 22 indexed citations

Skowronski, Danuta M., Macy Zou, Suzana Sabaiduc, et al.. (2020). Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020. Eurosurveillance. 25(7). 27 indexed citations

Skowronski, Danuta M., Suzana Sabaiduc, Catharine Chambers, et al.. (2020). Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016–2017 and 2017–2018 Epidemics in Canada. The Journal of Infectious Diseases. 225(8). 1387–1398. 28 indexed citations

Skowronski, Danuta M., Suzana Sabaiduc, Caren Rose, et al.. (2019). Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Eurosurveillance. 24(46). 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact